In this episode, the relatively new CEO of Elevation Oncology, Joseph Ferra, discusses the significant changes he has made at the company. These changes include transitioning from a monoclonal antibody candidate to a phase 1 Claudin18.2 target in the ADC space. The podcast also explores the importance of technology and being a platform company in the biotech industry, as well as the expansion of a clinical trial for gastric cancer treatment. Ferra emphasizes the need for planning and adaptability in the biotech industry to make the right decisions.